Liu M, Zou L, Zhang N, Zhou W, et al. Pathological response and metabolites' prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial. Breast Cancer Res 2025;27:190.
PMID: 41152909